Fenning_2015_J.Am.Heart.Assoc_4_

Reference

Title : Atherosclerotic plaque inflammation varies between vascular sites and correlates with response to inhibition of lipoprotein-associated phospholipase A2 - Fenning_2015_J.Am.Heart.Assoc_4_
Author(s) : Fenning RS , Burgert ME , Hamamdzic D , Peyster EG , Mohler ER , Kangovi S , Jucker BM , Lenhard SC , Macphee CH , Wilensky RL
Ref : J Am Heart Assoc , 4 : , 2015
Abstract :

BACKGROUND: Despite systemic exposure to risk factors, the circulatory system develops varying patterns of atherosclerosis for unclear reasons. In a porcine model, we investigated the relationship between site-specific lesion development and inflammatory pathways involved in the coronary arteries (CORs) and distal abdominal aortas (AAs). METHODS AND RESULTS: Diabetes mellitus (DM) and hypercholesterolemia (HC) were induced in 37 pigs with 3 healthy controls. Site-specific plaque development was studied by comparing plaque severity, macrophage infiltration, and inflammatory gene expression between CORs and AAs of 17 DM/HC pigs. To assess the role of lipoprotein-associated phospholipase A2 (Lp-PLA2) in plaque development, 20 DM/HC pigs were treated with the Lp-PLA2 inhibitor darapladib and compared with the 17 DM/HC untreated pigs. DM/HC caused site-specific differences in plaque severity. In the AAs, normalized plaque area was 4.4-fold higher (P<0.001) and there were more fibroatheromas (9 of the 17 animals had a fibroatheroma in the AA and not the COR, P=0.004), while normalized macrophage staining area was 1.5-fold higher (P=0.011) compared with CORs. DM/HC caused differential expression of 8 of 87 atherosclerotic genes studied, including 3 important in inflammation with higher expression in the CORs. Darapladib-induced attenuation of normalized plaque area was site-specific, as CORs responded 2.9-fold more than AAs (P=0.045). CONCLUSIONS: While plaque severity was worse in the AAs, inflammatory genes and inflammatory pathways that use Lp-PLA2 were more important in the CORs. Our results suggest fundamental differences in inflammation between vascular sites, an important finding for the development of novel anti-inflammatory therapeutics.

PubMedSearch : Fenning_2015_J.Am.Heart.Assoc_4_
PubMedID: 25672369

Related information

Inhibitor Darapladib

Citations formats

Fenning RS, Burgert ME, Hamamdzic D, Peyster EG, Mohler ER, Kangovi S, Jucker BM, Lenhard SC, Macphee CH, Wilensky RL (2015)
Atherosclerotic plaque inflammation varies between vascular sites and correlates with response to inhibition of lipoprotein-associated phospholipase A2
J Am Heart Assoc 4 :

Fenning RS, Burgert ME, Hamamdzic D, Peyster EG, Mohler ER, Kangovi S, Jucker BM, Lenhard SC, Macphee CH, Wilensky RL (2015)
J Am Heart Assoc 4 :